Search for: "Re v. PERS" Results 21 - 40 of 7,341
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Apr 2024, 9:30 pm by The Regulatory Review
The regulation is part of an effort to preserve the reproductive rights of women in the aftermath of the overturning of Roe v. [read post]
24 Apr 2024, 11:27 am by admin
Another multi-district litigation (MDL) has hit a jarring speed bump. [read post]
22 Apr 2024, 5:00 am by Bernard Bell
—, 144 S.Ct. 717 (March 15, 2024)(per curiam), the Supreme Court grappled with whether exercising such custodial control constituted “state action” for purposes of 42 U.S.C. [read post]
22 Apr 2024, 4:01 am by Deanne Sowter
The first two orders were by consent; the first granted the father one overnight stay with the child per week, and the second, two overnights per week. [read post]
In considering the criteria, Jackman J noted the Court must take into account the ‘transparency’ of the term, per s 12BG(2)(b), in addition to the contract as a whole, per s 12BG(2)(c), in interpreting unfairness. [read post]
16 Apr 2024, 9:01 pm by Vikram David Amar
A year ago, almost to the day, my (co-authored) Verdict column focused on the lessons to be learned from a high-profile and boisterous protest by Stanford Law School students at a Federalist Society Speaker Event featuring Judge Kyle Duncan, a conservative Trump-appointed judge on the United States Court of Appeals for the Fifth Circuit. [read post]
13 Apr 2024, 3:33 pm by admin
Prelude to Litigation Phenylpropanolamine (PPA) was a widely used direct α-adrenergic agonist used as a medication to control cold symptoms and to suppress appetite for weight loss.[1] In 1972, an over-the-counter (OTC) Advisory Review Panel considered the safety and efficacy of PPA-containing nasal decongestant medications, leading, in 1976, to a recommendation that the agency label these medications as “generally recognized as safe and effective. [read post]